Structure via PubChem · Public domain (PubChem)
valganciclovir
Sign in to saveAlso known as Ro-1079070/194, RS-079070-194, Valcyte®, Cymeval, L-valine, ester with ganciclovir
Valganciclovir, sold under the brand name Valcyte among others, is an antiviral medication used to treat cytomegalovirus (CMV) infection in those with HIV/AIDS or following organ transplant. It is often used long term as it only suppresses rather than cures the infection. Valganciclovir is taken by mouth.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 461740941
- Drug.image
- Valganciclovir structure.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250
- Drug.image2
- Valganciclovir ball-and-stick.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Valcyte, Valcip, others
- Drug.MedlinePlus
- a605021
- Drug.DailyMedID
- Valganciclovir
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- J05
- Drug.ATC_suffix
- AB14
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C14H22N6O5
- Molecular weight
- 354.36 g/mol
- IUPAC name
- [2-[(2-amino-6-oxo-1H-purin-9-yl)methoxy]-3-hydroxypropyl] (2S)-2-amino-3-methylbutanoate
- SMILES
- CC(C)[C@@H](C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N
- InChIKey
- WPVFJKSGQUFQAP-GKAPJAKFSA-N
- XLogP
- -1.5
- Polar surface area
- 167 Ų
- H-bond donors
- 4
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Research
2,071 papers- Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.JAMA · 2023
- A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients.Journal of the American Society of Nephrology : JASN · 2023
- Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2007
- Treatment for First Cytomegalovirus Infection Post-Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
- Valganciclovir: recent progress.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2010
via PubMed
~6 min read
Encyclopedic overview
13 sectionsContents
- Medical uses
- Adults
- Children
- Side effects
- Drug interactions
- Mechanism of action
- Pharmacokinetics
- Chemistry
- Society and culture
- Price and patent status
- Names
- References
- External links
Valganciclovir, sold under the brand name Valcyte among others, is an antiviral medication used to treat cytomegalovirus (CMV) infection in those with HIV/AIDS or following organ transplant. It is often used long term as it only suppresses rather than cures the infection. Valganciclovir is taken by mouth.
Common side effects include abdominal pain, headaches, trouble sleeping, nausea, fever, and low blood cell counts. Other side effects may include infertility and kidney problems. When used during pregnancy, it causes birth defects in some animals. Valganciclovir is the L-valyl ester of ganciclovir and works when broken down into ganciclovir by the intestine and liver.
Excerpted from Wikipedia’s “valganciclovir” article, available under the CC BY-SA 4.0 licence.